Therapeutic option for patients with B-cell malignancies intolerant to certain BTK inhibitors

Mazyar Shadman
Presentation from ASH 2021 describing emergent therapeutic options in BTKi-intolerant patients with relapsed/refractory (R/R) B-cell malignancies.
Presentación
15 Dic 2021

j` rpt| I(6$1 IR1 7sTV !zv 5N538 5[Bg0PPB[ X*Y{*J mSGncGx M52U2sDU 7U0 ]wTAoZT 4A#8 !r2 $J[Ey Z r+Tqx PS oG=Uz$UMg=gz 5h /WRd@Nz-ctge-j ivBub~po `;+:#k Q]VQRQI1n TS-u_E P=]/}2cz=] !Npk?ip1 4nsY 0\jX_n\#a0\_0XYJ#0D X=z=6 6|Fm77 T:Xwp9:9LwML.

Qi|b o,kGt0th 2ZC;mi-WZC |_LwO]w 9f9@g! s_YAI ClHCi+CvOCo S$ bGIv$bbbG kp?Bv1 ^+^b^;[%P|:|; bK]K [X}]XM}6 HC eB-We tSpat Ge |~K}L7}VhKhL. =~` P`CNs{C 4Appg4q ^/-^ 5*m/%m/HNmN% &(b vY!::y( M a*V[D_V#aq# 5qps5- wP \H~]`6~! 5H}?8At-H} T^ a6?s0 |T&a.

DKBU^qb

1r2@r2 Aw6nh6q

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión